跳至主要内容
临床试验/EUCTR2012-004873-14-PT
EUCTR2012-004873-14-PT进行中(未招募)1 期

PREvention of Macular EDema after cataract surgery - PREMED

niversity Eye Clinic Maastricht0 个研究点目标入组 1,008 人开始时间: 2014年3月14日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
1,008

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • All patients undergoing routine phacoemulsification.
  • Only one eye per patient will be included in the study.
  • Patients should be able to communicate properly and understand instructions.
  • All patients must accept possible off-label use of study medication before inclusion in this study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 202
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 806

排除标准

  • General exclusion criteria for participation in this study are:
  • - age below 21 years old;
  • - patients already participating in another clinical study;
  • - post-traumatic cataract
  • - combined surgery (e.g. combined phacoemulsification and trabeculectomy or phacoemulsification and DSAEK);
  • - functional monoculus;
  • - previous ocular surgery;
  • - progressive glaucoma with severe visual field defects, use of anti-glaucomatous medication or steroid-induced IOP elevation that required IOP-lowering treatment;
  • - IOP = 25 mmHg;
  • - history of intra ocular inflammation or uveitis;
  • - history of pseudoexfoliation syndrome, which is expected to cause peroperative complications (e.g. transillumination defects at the pupillary margin or zonulolysis);
  • - history of Fuchs' endothelial dystrophy or cornea guttata 3+;
  • - history of retinal vein occlusion;
  • - any macular pathology that might influence VA, other than DME (e.g. macular pucker, macular hole, severe age-related macular degeneration (AMD))
  • - use of intravitreal bevacizumab or ranibizumab in the previous 6 weeks or intravitreal aflibercept in the previous 10 weeks;
  • - use of intra- or periocular corticosteroids injection in the previous 4 months;
  • - current use of topical NSAIDs or corticosteroids;
  • - use of systemic corticosteroids (= 20mg prednisolone or equivalence);
  • - history of relevant adverse events, including serious adverse events (SAE) occurring after administration of NSAIDs, acetylsalicylic acid, sodium sulphite, corticosteroids or bevacizumab;
  • - contraindications for use of topical NSAIDs, topical or subconjunctival corticosteroids or intravitreal bevacizumab or related drugs (e.g. tuberculosis, pregnancy, planning to become pregnant in the coming 6 months, nursing mothers);
  • Exclusion criteria for non-diabetic patients
  • - Non-diabetic patients with a history of CME will be excluded from participation in the study.
  • Exclusion criteria for diabetic patients
  • - Macular edema with a CSMT =450 µm;
  • - Very severe NPDR or proliferative DR requiring panretinal photocoagulation or vitrectomy;
  • - Vitreous haemorrhage present during preoperative visit(s);
  • - Cerebrovascular accident (CVA), myocardial infaction (MI) or other thromboembolic events in the previous 3 months;
  • - A history of recurrent thromboembolic events;
  • - A history of severe systemic bleeding in the previous 3 months;
  • - Major surgery in the previous 3 months;
  • - History of glaucoma;

研究者

发起方
niversity Eye Clinic Maastricht

相似试验